Company: OFIX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-061062
Chunk: 59

Company: Orthofix Medical Inc.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 59
---
 Financial Officer (subject to certain acceleration provisions, as discussed under “—Potential Payments upon Termination or Change in Control” below). (6) Represents awards of time-based vesting restricted stock units and performance-based stock options granted under the Orthofix Medical Inc. 2024 CLO Inducement Plan upon Mr. Cedrón’s hire date of April 15, 2024 as Chief Legal Officer (subject to certain acceleration provisions, as discussed under “—Potential Payments upon Termination or Change in Control” below). (7) Represents awards of time-based vesting restricted stock units and time-based vesting stock options granted under the 2012 LTIP (subject to certain acceleration provisions, as discussed under “—Potential Payments upon Termination or Change in Control” below). (8) Represents awards of time-based vesting restricted stock units, performance-based stock options and time-based vesting stock options granted under the Orthofix Medical Inc. 2024 PGS Inducement Plan upon Mr. Reinhardt’s hire date of June 10, 2024 as President, Global Spine (subject to certain acceleration provisions, as discussed under “—Potential Payments upon Termination or Change in Control” below). (9) Represents awards of time-based vesting restricted stock units and performance-based stock options granted under the Orthofix Medical Inc. 2024 CP&BOO Inducement Plan upon Mr. Vitale’s hire date of March 15, 2024 as Chief People and Business Operations

<div align='center'>49</div>

Officer (subject to certain acceleration provisions, as discussed under “—Potential Payments upon Termination or Change in Control” below).

(10)Ms. Elting departed the Company as an employee and officer effective July 5, 2024, after eight years of executive officer service at the Company and executive leadership transition activities that provided her with the right to receive certain “good reason”-based severance payments and equity award acceleration rights upon resignation under her Change in Control and Severance Agreement. In connection with her separation, the Committee and Ms. Elting negotiated and entered into a separation and release agreement. This agreement memorialized Ms. Elting’s rights to receive payments and benefits under her Change in Control and Severance Agreement, accelerated certain time-based vesting equity awards granted in 2023 and 2024, and provided for a 12-month extension of her stock option exercise period from the length provided under her Change in Control and Severance Agreement.